Litcius/Paper detail

VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

Maximilian J. Hochmair, Karim Vermaelen, G. Mountzios, Enric Carcereny, Christophe Dooms, SH Lee, Éva Mórocz, Terufumi Kato, T-E. Ciuleanu, Grace K. Dy, Márcio Parente, Kenneth J. O’Byrne, Q.S-C. Chu, Gilberto de Castro, Nicolas Girard, Wendy Snyder, Qui Tran, William Kormany, Brett E. Houk, Alessandra Curioni‐Fontecedro

2023Annals of Oncology13 citationsDOI

Topics & Concepts

MedicineCmaxInternal medicineClinical endpointGastroenterologyPharmacokineticsConfidence intervalDosingRandomized controlled trialChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia TreatmentsColorectal Cancer Treatments and Studies
VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC | Litcius